|
17 Jan 2020 |
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
|
|
17 Jan 2020 |
BioNTech to acquire Neon to strengthen global leadership position in T cell therapies
|
|
17 Jan 2020 |
Rybelsus label updated with additional information from the PIONEER 6 CV outcomes trial
|
|
16 Jan 2020 |
PlantForm advances HIV antibody research in collaboration with scientists funded by U.S. National Institutes of Health
|
|
16 Jan 2020 |
Fibrocor and Galapagos sign expanded collaboration in fibrosis
|
|
15 Jan 2020 |
RECORDATI: Isturisa® (osilodrostat) approved
|
|
15 Jan 2020 |
Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products
|
|
15 Jan 2020 |
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
|
|
15 Jan 2020 |
Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy
|
|
15 Jan 2020 |
Janssen Seeks Expanded Use of SPRAVATO (Esketamine) Nasal Spray in Europe as a Treatment for Depressive Symptoms in Adults with Major Depressive Disorder Who Have Current Suicidal Ideation with Intent
|
|
15 Jan 2020 |
Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1
|
|
15 Jan 2020 |
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
|
|
15 Jan 2020 |
U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer
|
|
15 Jan 2020 |
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
|
|
15 Jan 2020 |
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
|
|
15 Jan 2020 |
Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase
|
|
15 Jan 2020 |
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
|
|
15 Jan 2020 |
Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease
|
|
15 Jan 2020 |
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein
|
|
15 Jan 2020 |
New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
|
